Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of M108 in Advanced Solid Tumors
NCT04894825Phase 1Recruiting
- Sponsor
- Beijing Mingzhi Zhishan Biotechnology
- Start
- Jun 2021
- Primary completion
- Jul 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of M108 in solid tumor, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and 1 more (2 arms), sponsored by Beijing Mingzhi Zhishan Biotechnology. Primary endpoints: Incidence of adverse events and Maximum Tolerated Dose at 21 days. Started Jun 2021; status: recruiting.
02
Drugs
M108
03
Conditions
solid tumorgastric adenocarcinomagastroesophageal junction adenocarcinomapancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04894825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04894825.